HCmed Innovations announced that former AstraZeneca Science and Innovation Director of Inhaled Drug Delivery Gunilla Petersson has joined the company as Chief Scientific Officer. Petersson has almost 30 years of experience in the pharmaceutical industry, primarily in inhaled drug development.
Taipei-based HCmed launched the Pulmogine handheld mesh nebulizer in 2019. In March 2022, the company announced a partnership with Formosa Laboratories and Formosa Pharmaceuticals to offer contract development and manufacturing services for inhaled drugs, and development projects with Cellics and AeroRx Therapeutics based on HCmed nebulizer technology have been announced over the past few years.
HCmed Chairman Jason Cheng commented, “We are thrilled to have Gunilla joining the HCmed team. Her extensive experience, proven track record of success with inhaled combination products, and understanding of international business operations make her the perfect candidate to lead our team. We believe that she will help HCmed explore new business opportunities and bring beneficial advantages to our company and pharmaceutical partners.”
Read the HCmed press release.
